#INO INOVIO 2024 Q3 Earnings: INOVIO reported a better-than-expected EPS and significant progress with its lead candidate INO-3107 in Q3 2024.

- Net Loss Q3 2024: $25.2M

- EPS Q3 2024: -$0.89 vs. Forecast -$1.20 (3 analysts)

- Cash Runway: Extends into Q3 2025

- INO-3107 BLA Submission: Mid-2025

"We continue to be focused on advancing INO-3107 and delivering a non-surgical option to RRP patients. Toward this goal, we expect to have all non-device modules for our BLA completed by year end, while in parallel we continue to implement the plan to resolve the previously announced manufacturing issue with the single-use array component of the device." - Dr. Jacqueline Shea, CEO

If you enjoyed this video, please like, subscribe, and hit the notification bell to stay updated with our latest stock analysis and market insights. Leave a comment below with your thoughts on the video, and any other stocks you'd like us to cover.

*Check out our latest videos on more earnings:*

- #AKYA Akoya Biosciences 2024 Q3 Earnings: [ Ссылка ]

- #LCTX Lineage Cell Therapeutics 2024 Q3 Earnings: [ Ссылка ]

- #NGS Natural Gas Services Group 2024 Q3 Earnings: [ Ссылка ]

- #HYLN Hyliion 2024 Q3 Earnings: [ Ссылка ]

- #CELC Celcuity 2024 Q3 Earnings: [ Ссылка ]

свернуть